From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Partial Resistance of Influenza B to Neuraminidase Inhibitors

Emergence of resistant strains and their transmissibility are both worrisome.

Resistance of influenza A to neuraminidase inhibitors (oseltamivir and zanamivir) has been reported, but the prevalence of influenza B resistance is unknown, as is the potential transmissibility of resistant strains.

Researchers used viral isolates from a 2004–2005 influenza B outbreak in Japan (where neuraminidase inhibitor use is particularly common) to study resistance in 74 infected children treated with oseltamivir and 348 infected patients (282 children) not treated with oseltamivir. With use of standard clinical and epidemiologic techniques for identifying resistance and transmissibility, partial neuraminidase inhibitor resistance was found in one treated child (1.4%) and seven untreated patients (2.0%). Of the resistant viruses isolated in the seven untreated patients, four appeared to have been transmitted in community settings, and three within family settings. The clinical course of infections was similar, regardless of resistance.

Comment: These data, while showing a low level of resistance compared with that found in influenza A (5%–18%) and somewhat speculative with regard to transmissibility, are worrisome and deserve follow-up. An editorialist notes that the possible transmissibility of resistant strains (previously thought unlikely) is even more disquieting than the development of resistance itself.

— Thomas L. Schwenk, MD

Published in Journal Watch General Medicine April 3, 2007

Citation(s):

Hatakeyama S et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007 Apr 4; 297:1435-42.

Moscona A and McKimm-Breschkin J. News about influenza B drug resistance that cannot be ignored. JAMA 2007 Apr 4; 297:1492-3.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Other Perspectives

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2007. Massachusetts Medical Society. All rights reserved.